A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer-Reference-Cited by-同舟云学术

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

Published:2016-01-25 Issue:3 Volume:5 Page:389-397
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

De Cock Erwin¹,Pivot Xavier²,Hauser Nik³,Verma Sunil⁴,Kritikou Persefoni⁵,Millar Douglas⁶,Knoop Ann⁷

Affiliation:

1. United BioSource Corporation; Barcelona Spain

2. CHU Jean Minjoz; Besançon France

3. Department of Gynecology and Obstetrics; Kantonsspital Baden AG; Baden Switzerland

4. Sunnybrook Odette Cancer Centre; Toronto Ontario Canada

5. United BioSource Corporation; Hammersmith United Kingdom

6. F. Hoffmann-La Roche Ltd; Basel Switzerland

7. Copenhagen University Hospital; Copenhagen Denmark

Funder

F. Hoffmann-La Roche Ltd, Basel, Switzerland

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.573/fullpdf

Reference10 articles.

1. Ferlay , J. I. Soerjomataram M. Ervik GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 http://globocan.iarc.fr

2. National Comprehensive Cancer Network 2016 NCCN Clinical Practice Guidelines in Oncology: Breast Cancer http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

3. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Senkus;Ann. Oncol.,2015

4. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015;Coates;Ann. Oncol.,2015

5. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial;Ismael;Lancet Oncol.,2012

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

2. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review;Frontiers in Pharmacology;2024-08-19

3. ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation;PharmacoEconomics - Open;2024-07-11

4. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases;Journal for ImmunoTherapy of Cancer;2024-07

5. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design;Advanced Drug Delivery Reviews;2024-06